Jun 2026 (Q2 FY26) — Aug 12, 2026
Octave Intelligence Q2 FY26 — Solid Performance Amidst Strategic Shift and Prudent Guidance
Read the full callOctave Intelligence earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 398 | −3.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -519.5 | −543.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -1,971 | −2721.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
YTD: $21.96 on 21 May 2026 → $20.52. High $25.11 (2 Jun 2026), low $15.5 (23 Jul 2026).
Overview
Call summaries
Octave Intelligence Q2 FY26 — Solid Performance Amidst Strategic Shift and Prudent Guidance
Read the full callEvery analysed call
Financials
Net profit, year on year: −2722% (quarter to jun 2026 against jun 2025).
| Line item | Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 383 | 413 | 387 | 398 |
| Operating profit | 74 | 97 | 64 | -2,070 |
| Operating margin | 19.3% | 23.4% | 16.5% | −519.5% |
| Interest | — | 0 | — | 2 |
| Profit before tax | 74 | 97 | 64 | -2,068 |
| Tax rate | 20.1% | 22.1% | 25.9% | 4.7% |
| Net profit | 59 | 75 | 47 | -1,971 |
| EPS ($ per share) | 0.22 | 0.28 | 0.18 | -7.34 |
No filings in the last 12 months.
No officer, director or 10% owner of OCTV filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow Octave Intelligence plc and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading